Organizing Committee Member

Ian James Martins

Ian James Martins

Advisory Board Member

Edith Cowan University



Dr Ian James Martins is an Editor/Reviewer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews: Neuroscience (2016-2018) and Journal of Diabetes and Clinical Studies (2017-2018). BIT Member (BIT Congress. Inc) with an h-index of 65, (ResearchGate STATs (28), Scopus Author ID: 7103152779/Mendeley STATS (21), UWA Research Repository (16). Scientist for The Science Advisory Board (USA) and an Academic with (220 Public Mentions). The citations past 27 years have accumulated to >4770. Ian James Martins - Semantic Scholar Profile Semantic Scholar profile for Ian James Martins, with fewer than 133 highly influential citations RESEARCHGATE ANALYSIS: Ian J Martins | Ph D | Centre of Excellence for Alzheimer's Disease ... under Ian James Martins’ name places publication Research Interest (1622) with an RG score (> 96%) of international SCIENTISTS. ORCID CONNECTING RESEARCHER: Editorial Team Editorial Team.

Research Area

Anti-Aging, Global Health and Chronic Disease . Keywords: Anti-Aging Genes, Appetite, Environment, Nutrition, Senescence IMPACT OF PREVIOUS RESEARCH TO THE FIELD OF MEDICINE AND LABORATORY TECHNOLOGY THAT MAY AVOID INADVERTENT ERRORS AND MAY TRANSLATE TO COMMERCIALISATION OF MEDICAL RESEARCH THAT determines CRITICAL HEALTH OUTCOMES. Development of a BLOOD TEST has been of critical interest to the for metabolic disease with relevance to diabetes and neurodegenerative diseases. Interests in Biomarker Research has escalated with relevance to mitochondrial survival and organ disease in diabetes and Alzheimer’s disease. The global chronic disease epidemic is expected to cost Biomarker Research between 15 to 20 billion dollars in the next 20 years. Biomarkers such as Sirtuin 1 are now relevant to mitochondrial apoptosis versus mitochondrial biogenesis and may supersede the various biomarkers for mitochondrial survival relevant to diabetes, Alzheimer’s disease and neurodegenerative disease research